Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?
Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald.
Posts Tagged ‘NASDAQ:MDVN’
Billionaire James Dinan’s York Capital Initiated Stakes in These Companies
Though billionaire James Dinan's York Capital Management manages regulatory assets worth over $25 billion, its latest 13F filing reveals that less than 16% of it or only $4 billion...
Huge Jumps In Hedge Fund Popularity For These 5 Healthcare Stocks
Biotechs have had a very tough year, though the healthcare sector as a whole has managed to rebound into the green year--to-date.
Why Pfizer, Medivation, GM, and 2 Other Stocks Have Investors Talking
After surging almost non-stop to $49 per barrel from $40, WTI futures are now 2% in the red while the broader indexes are pretty much flat in pre-market trading on the first trading...
5 Merger Arb Plays Added to Havens Advisors’ Portfolio in Q2
No matter how much things have changed over the past several years, Wall Street remains a place that is dominated by men.
10 Stocks That Had Their Price Targets Raised Tuesday
The markets opened higher today before sliding slightly into the red as investors await June’s data on import and export prices, the Treasury's budget report, and the latest...
Monday’s Trending Stocks: CBS, Medivation, HPE, Boeing, Sagent Pharmaceuticals
The benchmark S&P 500 index has jumped six points on Monday, setting a new all-time high as last week’s strong jobs report continues to buoy market sentiment.
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Here’s Why Medivation Inc (MDVN) Is in Spotlight Today
Markets opened higher today amid rising oil prices and a strong report from the U.S.
Why These Five Stocks Are Trending Today?
The US stock market plunged after the bell on the back of April nonfarm payrolls data, which showed that 160,000 jobs were created last month, versus 200,000 expected.
Why Apple (AAPL), Alphabet (GOOG), Pfizer (PFE) and Two Other Stocks are Trending Today
The markets are sliding on Wednesday after a report from Automatic Data Processing, which shows a decline in the growth of private sector employment.
Why Investors Are Buzzing About These Stocks Today
It's M&A Thursday, as several major M&A deals have been announced today.
Why These Five Stocks Are Deep in Red on Tuesday?
Markets opened lower on Tuesday amid a decline in crude prices that dragged lower many energy stocks.
Investors Can’t Get Enough of These 4 Stocks Today
With the S&P 500 and Dow Jones barely in the green as investors remain concerned about China's slowing economy, Big Lots, Inc.
Medivation Inc (MDVN): Are Hedge Funds Right About This Stock?
The equity market returns were very disappointing in the third quarter, “thanks” to the slowdown of China’s economy and the weaker-than-expected U.S. economic data.
Mariner Investment Group’s Top Biotech Stock Picks For Q4
Mariner Investment Group is a New York-based investment advisory firm founded by William Michaelcheck in 1992.
These Are Apex Capital Management’s Top Biotech Stock Picks
Founded in 1987, Apex Capital Management invests mainly in companies that have market caps of up to $10 billion and is currently overseeing $6.5 billion in assets under management...
AstraZeneca plc (ADR) (AZN), Johnson & Johnson (JNJ): Will the Exelixis, Inc. (EXEL) Hype Catch Up to Its Valuation?
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Hedge Fund Bets On Onyx Pharmaceuticals, Inc. (ONXX)
As fast as we can type this, Phill Gross and Robert Atchinson's hedge fund, Adage Capital Partners, disclosed ownership of about 3.7 million shares of Onyx Pharmaceuticals, ...
Incyte Corporation (INCY): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the 21st century investor’s toolkit, there are many gauges shareholders can use to track their holdings.
This Metric Says You Are Smart to Sell Ariad Pharmaceuticals, Inc. (ARIA)
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Should You Avoid Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ)?
In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings.
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
What Hedge Funds Think About Medivation Inc (MDVN)
In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets.
Is Illumina, Inc. (ILMN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Medivation Inc (MDVN), Dendreon Corporation (DNDN): 3 Positives From Johnson & Johnson (JNJ)’s Latest Acquisition
Johnson & Johnson (NYSE:JNJ) completed its acquisition of privately held Aragon Pharmaceuticals earlier this week. Plans for the deal were first announced by J&J in June.
Johnson & Johnson (JNJ): Biotechs With Prostate Cancer Treatments
There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer.
Medivation Inc (MDVN), Questcor Pharmaceuticals Inc (QCOR): The Best Performing Biotech Stocks of the Last Decade
Biotech is booming these days. But that's not a new story by any means. Biotech stocks as a group have done very well over the past several years.
Dendreon Corporation (DNDN): Is Time Running Out for This Fallen Biotech?
There’s a lot to notice from Johnson & Johnson (NYSE:JNJ)’s earnings -- the company announced a very solid quarter.
Medivation Inc (MDVN), Onyx Pharmaceuticals, Inc. (ONXX): Biotechs Take a Dive After a Standout Start to 2013
Are investors hitting the brakes on biotech? The biotech sector's one of the most boom-or-bust areas for investors, where fortunes can be won or lost.
Hedge Funds Are Buying Incyte Corporation (INCY)
Is Incyte Corporation (NASDAQ:INCY) a buy, sell, or hold? Investors who are in the know are taking an optimistic view.
Dendreon Corporation (DNDN): This Cancer Drug Developer Could Really Use a Partner
As we've learned over the past few years, getting a drug approved by the Food and Drug Administration is just half the battle in the biotech sector.
UnitedHealth Group Inc. (UNH), Aetna Inc. (AET): The Eight Biggest Health Problems Americans Face
The Centers for Disease Control and Prevention would put heart disease at the top of the list, since it's the leading cause of death in the nation.
Dendreon Corporation (DNDN) Searching For A Rebound
Where have we heard the fourth-quarter-comeback plan before? Oh yes, from Johnson's predecessor who issued 2011 revenue guidance of $350 million to $400 million, with half of ...
Dendreon Corporation (DNDN): What You Should Know
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Will Dendreon Corporation (DNDN) Ever Make Money?
On Thursday, Dendreon Corporation (NASDAQ:DNDN) will release its latest quarterly results.
Avanir Pharmaceuticals, Inc. (AVNR), Medivation Inc (MDVN) & This Week In Biotech
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Johnson & Johnson (JNJ): This Company’s Biggest Drug Rivals
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Medivation Inc (MDVN), Amarin Corporation plc (ADR) (AMRN), Abbott Laboratories (ABT): Adage Capital Management Owns 5.4% of This Company
According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation Inc...
Johnson & Johnson (JNJ), Dendreon Corporation (DNDN): A Magical Drug that Could Change Lives
The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it.
What’s Inside Johnson & Johnson (JNJ)’s Pharmaceuticals Business? – Medivation Inc (MDVN), Merck & Co., Inc. (MRK)
What doesn't Johnson & Johnson (NYSE:JNJ) produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Will Johnson & Johnson (JNJ) Help You Retire Rich?
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Johnson & Johnson (JNJ), Dendreon Corporation (DNDN) – Tackling Cancer: Prostate Cancer’s Biggest Current and Upcoming Players
As I commented last week, cancer statistics are both staggering and disappointing.
5 Can’t-Miss Health-Care Events This Week: Zogenix, Inc. (ZGNX), Ariad Pharmaceuticals, Inc. (ARIA)
Normally we have a nice blend of health-care events to take notice of each week.
Dendreon Corporation (DNDN) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Can Johnson & Johnson (JNJ)’s Zytiga Build on a Historic 2012?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal-care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
